Skip to main content
Erschienen in: Infection 5/2020

20.05.2020 | Images in Infection

Voriconazole-induced periostitis in stem cell transplant patient

verfasst von: Alexandre E. Malek, Yara Skaff, Victor E. Mulanovich

Erschienen in: Infection | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Excerpt

A 66-year-old woman with history of chronic kidney disease and T-cell lymphoma in remission after allogeneic hematopoietic stem cell transplantation (HCT) 5 years before, complicated by chronic skin graft-versus host disease off immunosuppression for 3 months before the current presentation. She was admitted with 4-week history of right ankle pain with no prior trauma or penetrating wound. She denied fever, fatigue or weight loss. The patient had invasive pulmonary aspergillosis, treated with voriconazole and kept on 200 mg twice daily as secondary prophylaxis for the last 4 years. Physical examination revealed distal right lower leg tenderness without inflammation. Laboratory studies showed white blood cell count, 5900/μL; creatinine, 1.59 mg/dL; mildly elevated alkaline phosphatase, 144 U/L (normal range 35–104 U/L). Ankle X-ray showed thick and irregular periostitis of distal tibia and fibula without any evidence of local tumor or infection (Fig. 1). Technetium bone scan showed increase cortical tracer uptake. The patient was diagnosed with voriconazole-induced periostitis. After discontinuing voriconazole, the bone pain started subsiding and patient remained free of symptoms on subsequent clinic follow-ups.
Literatur
1.
Zurück zum Zitat Wermers RA, Cooper K, Razonable RR, et al. Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. Clin Infect Dis. 2011;52:604–11.PubMed Wermers RA, Cooper K, Razonable RR, et al. Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. Clin Infect Dis. 2011;52:604–11.PubMed
2.
Zurück zum Zitat Bucknor MD, Gross AJ, Link TM. Voriconazole-induced periostitis in two post-transplant patients. J Radiol Case Rep. 2013;7:10.PubMedPubMedCentral Bucknor MD, Gross AJ, Link TM. Voriconazole-induced periostitis in two post-transplant patients. J Radiol Case Rep. 2013;7:10.PubMedPubMedCentral
3.
Zurück zum Zitat Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36:630–7.PubMed Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36:630–7.PubMed
4.
Zurück zum Zitat Barajas MR, McCullough KB, Merten JA, et al. Correlation of pain and fluoride concentration in allogeneic hematopoietic stem cell transplant recipients on voriconazole. Biol Blood Marrow Transpl. 2016;22:579–83. Barajas MR, McCullough KB, Merten JA, et al. Correlation of pain and fluoride concentration in allogeneic hematopoietic stem cell transplant recipients on voriconazole. Biol Blood Marrow Transpl. 2016;22:579–83.
5.
Zurück zum Zitat Moon WJ, Scheller EL, Suneja A, et al. Plasma fluoride level as a predictor of voriconazole-induced periostitis in patients with skeletal pain. Clin Infect Dis. 2014;59:1237–45.PubMedPubMedCentral Moon WJ, Scheller EL, Suneja A, et al. Plasma fluoride level as a predictor of voriconazole-induced periostitis in patients with skeletal pain. Clin Infect Dis. 2014;59:1237–45.PubMedPubMedCentral
6.
Zurück zum Zitat Gerber B, Guggenberger R, Fasler D, et al. Reversible skeletal disease and high fluoride serum levels in hematologic patients receiving voriconazole. Blood. 2012;120(12):2390–4.PubMed Gerber B, Guggenberger R, Fasler D, et al. Reversible skeletal disease and high fluoride serum levels in hematologic patients receiving voriconazole. Blood. 2012;120(12):2390–4.PubMed
7.
Zurück zum Zitat Levine MT, Chandrasekar PH. Adverse effects of voriconazole: over a decade of use. Clin Transpl. 2016;30:1377–86. Levine MT, Chandrasekar PH. Adverse effects of voriconazole: over a decade of use. Clin Transpl. 2016;30:1377–86.
Metadaten
Titel
Voriconazole-induced periostitis in stem cell transplant patient
verfasst von
Alexandre E. Malek
Yara Skaff
Victor E. Mulanovich
Publikationsdatum
20.05.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Infection / Ausgabe 5/2020
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-020-01445-0

Weitere Artikel der Ausgabe 5/2020

Infection 5/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.